Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kyntra Bio Inc (KYNB : NSDQ)

• Company Description    Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Kyntra Bio, formerly known as FibroGen Inc., is based in SAN FRANCISCO. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $6.99 Daily Weekly Monthly 20 Day Moving Average: 7,911 shares Shares Outstanding: 4.05 (millions) Market Capitalization: $28.30 (millions) Beta: 1.03 52 Week High: $12.60 52 Week Low: $4.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.30% -5.17% 12 Week 0.29% -7.29% Year To Date -20.39% -27.33%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 350 Bay Street Suite 100 #6009 - SAN FRANCISCO,CA 94133 USA ph: 415-978-1200 fax: 415-978-1902 ir@kyntrabio.com http://www.kyntrabio.com

• General Corporate Information    Officers Thane Wettig - Chief Executive Officer James A. Schoeneck - Chairman of the Board and Director David DeLucia - Senior Vice President and Chief Financial Officer Jeffrey L. Edwards - Director Maykin Ho - Director Peer Information Kyntra Bio Inc (CORR.) Kyntra Bio Inc (RSPI) Kyntra Bio Inc (CGXP) Kyntra Bio Inc (BGEN) Kyntra Bio Inc (GTBP) Kyntra Bio Inc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 31572Q881 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 4.05 Most Recent Split Date: 6.00 (0.04:1) Beta: 1.03 Market Capitalization: $28.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-13.89 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 3.80 EPS Growth vs. Year Ago Period: 6.50% vs. Previous Quarter: -3.60% Sales Growth vs. Year Ago Period: 36.47% vs. Previous Quarter: 192.49% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -36.71 12/31/25 - -34.39 09/30/25 - -26.27 Current Ratio 03/31/26 - 3.61 12/31/25 - 3.39 09/30/25 - 3.71 Quick Ratio 03/31/26 - 3.48 12/31/25 - 3.26 09/30/25 - 3.60 Operating Margin 03/31/26 - -671.32 12/31/25 - -800.81 09/30/25 - -549.90 Net Margin 03/31/26 - 2,199.13 12/31/25 - 2,848.19 09/30/25 - 2,598.55 Pre-Tax Margin 03/31/26 - -761.59 12/31/25 - -905.19 09/30/25 - -630.78 Book Value 03/31/26 - -7.60 12/31/25 - -4.20 09/30/25 - -0.99 Inventory Turnover 03/31/26 - 1.19 12/31/25 - 0.15 09/30/25 - -1.59 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©